Data Insights

JZP-898 by Jazz Pharmaceuticals for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

JZP-898 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - JZP-898 in Metastatic Hepatocellular Carcinoma (HCC)

Data Insights

JZP-898 by Jazz Pharmaceuticals for Metastatic Melanoma: Likelihood of Approval

JZP-898 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - JZP-898 in Metastatic Melanoma

Data Insights

JZP-898 by Jazz Pharmaceuticals for Solid Tumor: Likelihood of Approval

JZP-898 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - JZP-898 in Solid Tumor

Data Insights

JZP-898 by Jazz Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval

JZP-898 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - JZP-898 in Non-Small Cell Lung Cancer

Data Insights

JZP-898 by Jazz Pharmaceuticals for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

JZP-898 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to...

Likelihood of Approval and Phase Transition Success Rate Model - JZP-898 in Gastroesophageal (GE) Junction Carcinomas

Data Insights

JZP-898 by Jazz Pharmaceuticals for Metastatic Colorectal Cancer: Likelihood of Approval

JZP-898 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - JZP-898 in Metastatic Colorectal Cancer

Data Insights

JZP-898 by Jazz Pharmaceuticals for Metastatic Renal Cell Carcinoma: Likelihood of Approval

JZP-898 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Metastatic Renal Cell Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - JZP-898 in Metastatic Renal Cell Carcinoma

Data Insights

JZP-898 by Jazz Pharmaceuticals for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

JZP-898 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - JZP-898 in Metastatic Transitional (Urothelial) Tract Cancer

Data Insights

JZP-898 by Jazz Pharmaceuticals for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

JZP-898 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - JZP-898 in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Risk adjusted net present value: What is the current valuation of Jazz Pharmaceuticals's JZP-898?

JZP-898 is a fusion protein commercialized by Jazz Pharmaceuticals, with a leading Phase I program in Metastatic Transitional (Urothelial) Tract...

Net Present Value Model: Jazz Pharmaceuticals Plc's JZP-898